dofequidar
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 1999 (NCT00004886)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bile salt export pumpINHIBITOR
ABCB11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2cccc3ncccc23)CC1- Mol. weight
- 481.6 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL65067 ↗
Also known as
- dofequidar
- dofequidar
- dofequidar
- dofequidar fumarate
- dofequidar fumarate
- dofequidar (fumarate)
- ms 209
- ms 209
- ms-209
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004886 | Phase 1 | Dec 1, 1999 | Curie Institute, European Organisation for Research and Treatment of Cancer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Curie Institute | Academic/Hospital | 1 | 0 | 1 | 1999 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 1999 |
2 organizations
Page 1 / 1